Vaccine optimism and hopes of an end to coronavirus quarantines and lockdowns are spurring growth among emerging markets-focused hedge fund managers, new industry analysis shows.
BTIG employees will not be required to return to any of the firm’s US offices prior to Labor Day of 2021.
By George Ralph (pictured), Managing Director, RFA – The coronavirus pandemic has brought considerable challenges to the way hedge funds and asset management firms do business, with far-reaching consequences for cybersecurity, data safety and business communications. The need for fully flexible working around the pandemic continues to change. Collaboration tools have been key to successful working environments as staff need to work in the same way and securely, regardless of location.
K2 Advisors, the hedge fund investing unit of Franklin Templeton, says active-management alpha will be critical to hedge funds’ success this year, as the global economy mounts a tentative recovery from the coronavirus pandemic.
The Depository Trust & Clearing Corporation (DTCC) has identified the key priorities where financial market infrastructures (FMIs) should focus in the coming years to proactively and effectively manage risk in a post-pandemic environment.
As the rollout of Covid-19 vaccines continues apace, equity markets look set to enjoy strong support in 2021, says Luca Paolini, chief strategist at Pictet Asset Management…
This year’s Covid-19 stock market upheaval has revealed an “Achilles’ heel” in quantitative hedge fund models that use traditional factors such as momentum and value, as machine-based strategies have struggled against “unique new drivers of stock returns that don’t fit the academic models”, says Man FRM.
2020 has been a reminder that unforeseen circumstances can cause even the most stable of investment environments to switch quickly into being unpredictable and volatile.
UK hedge fund Argonaut takes aim at AstraZeneca-Oxford vaccine and warns against “silver bullet” recovery
The recent stock market “exuberance” sparked off by breakthroughs in Covid-19 vaccine trials may give way to disappointment next year, says Argonaut Capital CEO and CIO Barry Norris, who continues to build short positions in a number of drug companies, including AstraZeneca, amid continued uncertainty over efficacy and dosage in its trial process.
Optimal opportunities: Why current volatility levels are proving a “sweet spot” for alpha-focused funds
Markets look set to remain in a “sweet spot” of heightened volatility – driven by Covid-19 uncertainty and the fallout from the US presidential election – offering a wealth of opportunities for alpha-focused strategies.